IDSAB2007: #477

ANTIMICROBIAL SUSCEPTIBILITY OF GRAM-POSITIVE ORGANISMS ISOLATED FROM NORTH AMERICAN HOSPITALS: RESULTS FROM THE DAPTOMYCIN SURVEILLANCE PROGRAM, 2004 – 2006

Helio S. SADER, Thomas R. FRITSCHE, Ronald H. JONES

JMI Laboratories, North Liberty, IA, USA

ABSTRACT

Infective endocarditis, particularly in intravenous drug abusers, is the most common form of perivalvular abscess formation. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci. For daptomycin and comparator agents, susceptibility was determined using the broth microdilution method of the Clinical Laboratory Standards Institute (CLSI). Samples were tested at NTIDSA-IPM and at collaborating centers participating in the Daptomycin Surveillance Program.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

INTRODUCTION

Infective endocarditis, particularly in intravenous drug abusers, is the most common form of perivalvular abscess formation. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci. For daptomycin and comparator agents, susceptibility was determined using the broth microdilution method of the Clinical Laboratory Standards Institute (CLSI). Samples were tested at NTIDSA-IPM and at collaborating centers participating in the Daptomycin Surveillance Program.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

MATERIALS AND METHODS

N. bacteremia, including right-sided endocarditis. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

SELECTED REFERENCES

The most common pathogens were S. aureus, Enterococcus faecalis, and Streptococcus pneumoniae. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

SELECTED REFERENCES

The most common pathogens were S. aureus, Enterococcus faecalis, and Streptococcus pneumoniae. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

SELECTED REFERENCES

The most common pathogens were S. aureus, Enterococcus faecalis, and Streptococcus pneumoniae. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.

SELECTED REFERENCES

The most common pathogens were S. aureus, Enterococcus faecalis, and Streptococcus pneumoniae. We evaluated DAP activity tested against GP organisms collected in North American hospitals for the 3-year period following DAP approval.

RESULTS

Daptomycin was approved by the United States Food and Drug Administration (US-FDA) and by the European Medicine Agency (EMEA) for the treatment of complicated skin and skin structure infections caused by oxacillin-susceptible and –resistant staphylococci.

A Cochrane review updated in 2009 showed that the use of daptomycin can reduce serious infections in patients at risk.